302 related articles for article (PubMed ID: 36359850)
21. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
22. Crocetin attenuates the oxidative stress, inflammation and apoptosisin arsenic trioxide-induced nephrotoxic rats: Implication of PI3K/AKT pathway.
Liu P; Xue Y; Zheng B; Liang Y; Zhang J; Shi J; Chu X; Han X; Chu L
Int Immunopharmacol; 2020 Nov; 88():106959. PubMed ID: 32919218
[TBL] [Abstract][Full Text] [Related]
23. Searching for treatments for non-G12C-KRAS mutant cancers.
Guo C; Banerji U
Br J Cancer; 2021 Aug; 125(5):625-626. PubMed ID: 33859342
[TBL] [Abstract][Full Text] [Related]
24. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
25. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
26. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
Iskandar K; Rezlan M; Yadav SK; Foo CH; Sethi G; Qiang Y; Bellot GL; Pervaiz S
Antioxid Redox Signal; 2016 May; 24(14):781-94. PubMed ID: 26714745
[TBL] [Abstract][Full Text] [Related]
27. Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.
Terado T; Kim CJ; Ushio A; Minami K; Tambe Y; Kageyama S; Kawauchi A; Tsunoda T; Shirasawa S; Tanaka H; Inoue H
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35894141
[TBL] [Abstract][Full Text] [Related]
28. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
29. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
30. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.
Hamilton G; Plangger A
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1065-1074. PubMed ID: 34347509
[TBL] [Abstract][Full Text] [Related]
33. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
Liu H; Qian F
Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
[TBL] [Abstract][Full Text] [Related]
34. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
[TBL] [Abstract][Full Text] [Related]
35. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
36. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
[TBL] [Abstract][Full Text] [Related]
37. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
[TBL] [Abstract][Full Text] [Related]
38. Toxic effects of arsenic trioxide on spermatogonia are associated with oxidative stress, mitochondrial dysfunction, autophagy and metabolomic alterations.
Chen H; Liu G; Qiao N; Kang Z; Hu L; Liao J; Yang F; Pang C; Liu B; Zeng Q; Li Y; Li Y
Ecotoxicol Environ Saf; 2020 Mar; 190():110063. PubMed ID: 31846860
[TBL] [Abstract][Full Text] [Related]
39. Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.
Liou GY; Döppler H; DelGiorno KE; Zhang L; Leitges M; Crawford HC; Murphy MP; Storz P
Cell Rep; 2016 Mar; 14(10):2325-36. PubMed ID: 26947075
[TBL] [Abstract][Full Text] [Related]
40. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
